Platelet prostanoid receptors.

@article{Armstrong1996PlateletPR,
  title={Platelet prostanoid receptors.},
  author={R. Armstrong},
  journal={Pharmacology \& therapeutics},
  year={1996},
  volume={72 3},
  pages={
          171-91
        }
}
  • R. Armstrong
  • Published 1996
  • Chemistry, Medicine
  • Pharmacology & therapeutics
Prostaglandins (PGs) and thromboxanes are important modulators of platelet activation, and there is strong evidence to support the existence of distinct thromboxane, prostacyclin, PGD2 and PGE2 receptors on the platelet plasma membrane. In this review, each of these platelet prostanoid receptors is discussed in detail, with respect to their receptor pharmacology, molecular biology and signal transduction, and as to any therapeutic implications of the development of specific agonists and/or… Expand
Platelet Thromboxane Receptors: Biology and Function
Thromboxane A2 (TXA2), is a product of the cyclooxygenase pathway of arachidonic acid metabolism with platelet activation, vascular and bronchial smooth muscle constrictive and smooth muscleExpand
Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation.
TLDR
It is suggested that local production of PGE2 during an inflammatory process can modulate ensuing platelet responses, and loss of the EP3 receptor in a model of venous inflammation protects against formation of intravascular clots. Expand
P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation
TLDR
It is demonstrated that PGI2 and NO synergize with P2Y12 receptor antagonists to produce powerful platelet inhibition and the concept of refining ex vivo platelet function testing by incorporating an assessment of endothelial function to predict thrombotic outcomes better and adjust therapy to prevent adverse outcomes in individual patients is introduced. Expand
Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti‐platelet therapy
Endothelium‐derived prostacyclin and nitric oxide elevate platelet cyclic nucleotide levels and maintain quiescence. We previously demonstrated that a synergistic relationship exists between cyclicExpand
Inhibition of Platelet Function by the Endothelium
Thromboregulation is the communication between endothelial cells and platelets to contain clot formation so that proper blood flow and vessel repair can occur simultaneously. There are three separateExpand
Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors.
TLDR
A mathematical model integrating the pathway components was established which successfully reproduces the observed platelet responses and could show for the first time the reciprocal action of the endogenous prostaglandin PGE2 on platelets by functional responses and phosphorylation events. Expand
Tweaking the gain on platelet regulation: the tachykinin connection.
TLDR
Initial analysis of the role of the neurokinin-1 receptor in platelet thrombus formation, and thrombosis in the mouse, indicate this to be a promising new target for the development of anti-thrombotic drugs. Expand
P2Y12 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP
TLDR
The ability of the P2Y12 antagonists cangrelor, ticagrelor and prasugrel active metabolite (PAM), and the EP3 antagonist DG-041 to promote the inhibitory effects of modulators of platelet aggregation that act via cAMP is investigated. Expand
Comparison of Anti-Aggregatory Effects of PGI2, PGI3 and Iloprost on Human and Rabbit Platelets
TLDR
The rank orders of agonist potency are different in rabbit compared to those of human, which indicates that the prostacyclin receptors of rabbit platelets are pharmacologically different from those ofhuman. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 234 REFERENCES
Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects.
TLDR
This work suggests that hyperaggregability of diabetic platelets is not due to any alteration of platelet prostacyclin receptor numbers or their activation. Expand
Modulation of human platelet adenylate cyclase by prostacyclin (PGX).
TLDR
A model of platelet homeostasis is proposed that suggests platelet aggregation is controlled by a balance between the adenylate cyclase stimulating activity of prostacyclin, and the cAMP lowering activity of PGH2. Expand
Cellular Activation of Thromboxane Receptors a
TLDR
An F prostaglandin isomer, 8-epi-PGF2 alpha, which exerts its biological effects through a thromboxane (or closely related) receptor, which can be generated in a free radical-catalyzed or cyclooxygenase-dependent manner. Expand
Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins.
TLDR
Platelet aggregation and secretion induced by PGG 2 and by analogues of PGH 2 and PGE 2 were inhibited by NO164 and responses to ADP, vasopressin and arachidonic acid were unaffected. Expand
Stimulation of human platelet adenylate cyclase by prostaglandin D2.
TLDR
A number of minor differences in the response of platelets to PGD 2 and PGE 1 suggest the existence of at least two prostaglandin receptors influencing a single adenylate cyclase. Expand
PROSTAGLANDINS AND THROMBOXANES
Publisher Summary There is now a better understanding of the physiological role of prostaglandins. Major significance has been the discovery that aspirin, indoinethacin and other non-steroidExpand
Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics
TLDR
The results indicate that EP 035 and EP 157 inhibit the aggregation of human platelets by acting as agonists at the PGI2 receptor linked to adenylate cyclase. Expand
Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders.
TLDR
Why these drugs can be more efficacious than traditional antiplatelet agents is explained here and the available experimental studies involving these drugs are reviewed. Expand
Prostaglandin D2 inhibits the aggregation of human platelets.
Abstract Prostaglandin D2, heretofore considered to be biologically inactive, was found to be more than twice as potent as prostaglandin E1 as an inhibitor of aggregation in human citratedExpand
Separate receptors for prostacyclin and prostaglandin E2 on human gel-filtered platelets.
Human gel-filtered platelets (GFP) and radiolabeled prostacyclin (PGI2), prostaglandin (PG) E2 and PGE1 were used to ascertain whether PGI2 and PGs of the E series share a common receptor or haveExpand
...
1
2
3
4
5
...